In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Poster Session 5: Atrial fibrillation and oral anticoagulation 5
Session

Event : ESC Congress 2019

Topic : European Society of Cardiology

  • Session type : Poster Session
  • Date : 02 September 2019
  • Time : 14:00 - 18:00

9 presentations in this session

Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis

Event : ESC Congress 2019

  • Session : Atrial fibrillation and oral anticoagulation 5
  • Speaker : GYH Lip (Liverpool,GB)

Efficacy and safety of dronedarone by duration of atrial fibrillation history: a post-hoc analysis of the ATHENA trial

Event : ESC Congress 2019

  • Session : Atrial fibrillation and oral anticoagulation 5
  • Speaker : C Blomstrom-Lundqvist (Uppsala,SE)

Use of direct oral anticoagulants in patients with atrial fibrillation having a history of intracranial hemorrhage

Event : ESC Congress 2019

  • Session : Atrial fibrillation and oral anticoagulation 5
  • Speaker : T Chao (Taipei,TW)

Comparisons of direct oral anticoagulants and warfarin in patients with atrial fibrillation and liver cirrhosis

Event : ESC Congress 2019

  • Session : Atrial fibrillation and oral anticoagulation 5
  • Speaker : T Chao (Taipei,TW)

Haematuria is not elevated in AF patients treated with NOACs versus VKAs: GARFIELD-AF study

Event : ESC Congress 2019

  • Session : Atrial fibrillation and oral anticoagulation 5
  • Speaker : S Verstraete (Knokke-Heist,BE)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are